GSK3B and familial pancreatic carcinoma: Introducing WT-GSK-3β increased the IC50s of MIA-PaCa-2 pancreatic cancer cells to many drugs commonly used to treat PDAC, while WT-GSK-3 increased the sensitivity of MCF-7 breast cancer cells to certain drugs, signal transduction inhibitors, and nutraceuticals.